278 related articles for article (PubMed ID: 15322567)
1. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection.
da Silva MG; Pimentel P; Carvalhais A; Barbosa I; Machado A; Campilho F; Sousa SR; Miranda N; da Costa FL; Campos A; Vaz CP; Antas J; Passos-Coelho JL
Bone Marrow Transplant; 2004 Oct; 34(8):683-91. PubMed ID: 15322567
[TBL] [Abstract][Full Text] [Related]
2. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
4. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B
Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728
[TBL] [Abstract][Full Text] [Related]
5. PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients.
Gasová Z; Marinov I; Vodvárková S; Böhmová M; Bhuyian-Ludvíková Z
Transfus Apher Sci; 2005 Apr; 32(2):167-76. PubMed ID: 15784451
[TBL] [Abstract][Full Text] [Related]
6. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
7. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
8. Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield.
Díaz MA; Garcia-Sanchez F; Lillo R; Vicent MG; Vicario JL; Madero L
Haematologica; 1999 Jan; 84(1):32-5. PubMed ID: 10091391
[TBL] [Abstract][Full Text] [Related]
9. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
11. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
12. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
14. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
[TBL] [Abstract][Full Text] [Related]
15. PBPC collections: Management, techniques and risks.
Gašová Z; Bhuiyan-Ludvíková Z; Böhmová M; Marinov I; Vacková B; Pohlreich D; Trněný M
Transfus Apher Sci; 2010 Oct; 43(2):237-43. PubMed ID: 20678961
[TBL] [Abstract][Full Text] [Related]
16. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
[TBL] [Abstract][Full Text] [Related]
17. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience.
Lapierre V; Rossi JF; Heshmati F; Azar N; Vekhof A; Makowski C; Moreau P; Caillot D; Auperin A; Chabannon C
Bone Marrow Transplant; 2011 Jul; 46(7):936-42. PubMed ID: 20956952
[TBL] [Abstract][Full Text] [Related]
18. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
[TBL] [Abstract][Full Text] [Related]
19. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
20. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]